Kentucky Medicaid spending on GLP-1 drugs

How much did Kentucky Medicaid spend on GLP-1 drugs like Ozempic and Mounjaro in 2025?

Pharmacies were reimbursed at least $238.3 million for GLP-1 drugs paid through Kentucky Medicaid in 2025, across at least 274,538 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 97 rows of 292, so these figures are floors.

Pharmacies were reimbursed at least $48.1 million for GLP-1 drugs paid through Kentucky Medicaid in 2026 (quarter 1 only, as posted so far), across at least 57,534 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 30 rows of 79, so these figures are floors.

By year and ingredient

2020at least $13,580,055No dataat least $12,150,316at least $8,124,872at least $5,637,824at least $371,363at least $144,493at least $40,008,923
2021at least $11,818,930No dataat least $11,319,880at least $42,421,683at least $3,742,784at least $502,354at least $102,980at least $69,908,611
2022at least $45,594,260at least $4,118,144$5,776,833at least $34,192,039at least $2,487,571at least $2,315,171$137,051at least $94,621,070
2023at least $95,339,729at least $52,913,225at least $4,056,303at least $24,411,964at least $1,395,908at least $476,790at least $89,314at least $178,683,232
2024at least $131,990,799at least $71,351,566at least $2,100,089at least $12,803,846at least $577,742at least $323,261at least $114,964at least $219,262,267
2025at least $154,487,657at least $60,652,091at least $665,959at least $22,105,383at least $84,058at least $249,348at least $70,075at least $238,314,570
2026 (Q1)at least $29,764,827at least $13,519,570at least $96,389$4,634,779Suppressed$54,945$22,048at least $48,092,559

By product, 2025

Ozempicat least $151,461,445at least 176,5293 of 34
Rybelsusat least $2,072,515at least 2,5244 of 23
Wegovyat least $953,697at least 8255 of 25
Mounjaroat least $58,276,549at least 63,82619 of 69
Zepboundat least $2,375,542at least 2,43216 of 28
Liraglutide (generic name listing)at least $50,046at least 14822 of 32
Victozaat least $615,912at least 1,3115 of 15
Trulicityat least $22,105,383at least 26,45012 of 45
Bydureon$74,1501090 of 2
Byettaat least $9,908at least 164 of 5
Exenatide (generic name listing)SuppressedSuppressed3 of 3
Soliquaat least $249,348at least 3063 of 7
Xultophyat least $70,075at least 621 of 4

By quarter, 2025

Q1 2025at least $58,903,613at least 68,25018 of 67
Q2 2025at least $62,713,904at least 72,40325 of 71
Q3 2025at least $61,687,377at least 70,76726 of 76
Q4 2025at least $55,009,677at least 63,11828 of 78

By quarter, 2026 (posted so far)

Q1 2026at least $48,092,559at least 57,53430 of 79

The amounts are CMS’s “Total Amount Reimbursed” field. CMS’s data dictionary for State Drug Utilization Data says of it:

“This total is not reduced or affected by Medicaid rebates paid to the state. This amount represents both the Federal and State Reimbursement and is inclusive of dispensing fees.”

Its prescription count is “The number of prescriptions reimbursed (by the Medicaid Program ONLY) to pharmacists for the (11-digit NDC) drug for the period covered.”

CMS suppresses some rows (its “Suppression Used” field is true and the counts and amounts are left blank). Here a suppressed row is never counted as zero: a figure that includes suppressed rows is shown as “at least” the sum of the rows CMS did publish, and a figure where every row is suppressed is shown as “Suppressed.” The “Rows suppressed” column gives the count. Where many rows are suppressed, the published sum can be well below the full amount, so floors for different states are not directly comparable.

Fee-for-service and managed care rows are added together. Other states: Medicare and Medicaid spending on GLP-1 drugs.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.